The Record... (cont'd)
Ric,
That's a great way to get the literature references. Thanks for thinking of it.
I also understand that Adis does some evaluative ratings on drugs. What criteria do they use? Can you get me their ratings on vatalanib?
Sharon
I'm glad Sharon asked about the way Adis does its rating.
Adis has developed a highly structured system to provide a rating guide for the clinical potential of new agents undergoing research and development. Compounds of commercial interest have been rated on their likely therapeutic potential by the Adis editorial staff.
The system is based on the assignment of a numerical score of up to 20 key evaluation criteria. The ratings are derived from the literature available at the time the evaluation is undertaken. The Evaluation is added as soon as there is sufficient published information to allow a Rating to be derived. It is unlikely that this will be at the time when a record is first established.
Ratings for compounds can be one of five types: Preclinical rating: chemistry and pharmacodynamics, Clinical pharmacokinetics rating, Clinical efficacy and use rating, Clinical Safety, and Clinical outcome and pharmacoeconomic, depending upon the information available which, in turn, is generally related to the phase of development of a compound.
The Adis editors rate compounds in late-stage development, (e.g. phase II/III, III) preregistration, and provides associated commentary.
Check the rating from the record below and go to the next page.
ADIS Evaluation: Solid tumours 76 (PO).
Go to the next page.
